The Influence of FK-506 and Low-Concentration Ciclosporin on Human Lymphocyte Activation Antigen Expression and Blastogenesis: a Flow Cytometric Analysis
- 1 March 1990
- journal article
- research article
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 31 (3) , 297-304
- https://doi.org/10.1111/j.1365-3083.1990.tb02772.x
Abstract
The influence of FK-506 and ciclosporin (CsA), either alone or in combination, on PHA- and alloantigen-induced human blood lymphocyte transformation was investigated. The concentrations of FK-506 and CsA required to cause 50% inhibition of mitogen-induced thymidine incorporation were 1.0 and 200 ng/ml respectively. Evidence of synergistic inhibition of DNA synthesis was obtained when doses of each drug below these concentrations were combined (FK-506, ≤0.5 ng/ml; CsA ≤50 ng/ml). In contrast, FK-506 and CsA failed to inhibit PHA-induced increases in cell size and granularity determined by flow cytometric analysis at 1 and 3 days of culture. Moreover, no significant changes in the expression of the interleukin 2 receptor (IL-2R; CD25), transferrin receptor (TR; CD7I) or HLA-DR were observed in terms of percentage positive lymphocytes or mean cell surface membrane fluorescence intensity. In primary mixed lymphocyte cultures, 50% inhibition of thymidine incorporation was obtained with FK-506 and CsA concentrations of approximately 0.25 and 25 ng/ml respectively. Evidence of synergy was obtained when lower doses of each drug were combined (FK-506, ≤0.1 ng/ml; CsA ≤2 ng/ml). On their own, these concentrations of CsA were ineffective. In contrast to corresponding PHA-stimulated cells, FK-506-treated alloactivated lymphocytes exhibited reductions in IL-2R, TR and HLA-DR antigen expression, which in the cases of IL-2R and TR were further reduced by combination of FK-506 with low-concentration CsA. These data provide further evidence of the potential of combined low-dosage FK-506 and CsA for the control of human T-cell activation and proliferation in response to allostimulation.This publication has 15 references indexed in Scilit:
- EFFECT OF A NEW IMMUNOSUPPRESSIVE AGENT, FK506, ON HUMAN LYMPHOCYTE RESPONSES IN VITROTransplantation, 1989
- EFFECT OF A NEW IMMUNOSUPPRESSIVE AGENT, FK506, ON HUMAN LYMPHOCYTE RESPONSES IN VITROTransplantation, 1989
- FK-506 — How much potential?Immunology Today, 1989
- IMMUNOSUPPRESSIVE ACTIVITY, LYMPHOCYTE SUBSET ANALYSIS, AND ACUTE TOXICITY OF FK-506 IN THE RAT. A COMPARATIVE AND COMBINATION STUDY WITH CYCLOSPORINETransplantation, 1989
- Cyclosporin a does not inhibit the PHA‐stimulated increase in intracellular Ca2+ concentration but inhibits the increase in e‐rosette receptor (CD2) expression and appearance of interleukin‐2 receptors (CD25)Cytometry, 1988
- PROLONGATION OF SKIN ALLOGRAFT SURVIVAL IN RATS BY A NOVEL IMMUNOSUPPRESSIVE AGENT, FK 506Transplantation, 1988
- STUDIES OF THE INDUCTION AND MAINTENANCE OF LONG-TERM GRAFT ACCEPTANCE BY TREATMENT WITH FK506 IN HETEROTOPIC CARDIAC ALLOTRANSPLANTATION IN RATSTransplantation, 1987
- STUDIES OF THE EFFECTS OF FK506 ON RENAL ALLOGRAFTING IN THE BEAGLE DOGTransplantation, 1987
- FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics.The Journal of Antibiotics, 1987
- The Interleukin-2 T-Cell System: A New Cell Growth ModelScience, 1984